LE
LEXX.US Lexaria Bioscience Corp
- Market cap
- USD 9.35M
- P/E
- -
- P/B
- 1.97x
- ROE
- -141.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to May 2026.
Is LEXX.US undervalued?
Graham numberThe Graham number of Lexaria Bioscience Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lexaria Bioscience Corp fundamental analysis
No fundamental analysis for Lexaria Bioscience Corp yet.
Lexaria Bioscience Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lexaria Bioscience Corp
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion method…
Full company profileLexaria Bioscience Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to May 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lexaria Bioscience Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 40.7K | 63.6K | 433K | 223K | 385K | 723K | 255K | 226K | 464K | 706K | 26.7K |
| Gross Profit | -4.90K | 33.9K | 408K | 200K | 215K | 547K | 184K | 195K | 459K | 703K | -5.60K |
| Operating Income | -1.23M | -1.85M | -6.60M | -4.06M | -4.15M | -5.69M | -6.62M | -6.53M | -5.75M | -11.9M | -6.69M |
| EBITDA | -1.27M | -1.92M | -6.60M | -4.00M | -4.00M | -4.02M | -7.28M | -6.57M | -5.73M | -11.8M | -6.64M |
| Net Income | -1.21M | -1.87M | -6.60M | -4.10M | -3.93M | -4.03M | -7.27M | -6.66M | -5.80M | -11.9M | -6.71M |
| EPS | -12 | -14 | -42 | -24 | -21 | -14 | -19 | -15 | -7.02 | -9.92 | -4.06 |
| Balance Sheet | |||||||||||
| Total Assets | 567K | 2.86M | 2.43M | 2.68M | 2.83M | 13.3M | 7.83M | 3.08M | 8.87M | 4.18M | 4.78M |
| Total Liabilities | 479K | 92.3K | 43.6K | 185K | 346K | 203K | 201K | 404K | 1.21M | 1.57M | 437K |
| Shareholders' Equity | 266K | 3.01M | 2.39M | 2.38M | 2.53M | 13.3M | 7.95M | 3.04M | 8.04M | 2.99M | 4.74M |
| Cash & Short-term Investments | 93.4K | 2.53M | 1.74M | 1.35M | 1.31M | 11.8M | 6.16M | 1.48M | 6.56M | 1.97M | 3.62M |
| Total Debt | 45.0K | 42.7K | 7.86K | - | 156K | 97.3K | 50.0K | 164K | 137K | 109K | 86.7K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -661K | -1.55M | -2.52M | -3.01M | -2.62M | -3.99M | -4.88M | -5.88M | -4.96M | -10.5M | -6.38M |
| Capital Expenditure | 20.1K | 9.70K | 85.4K | 769K | 33.6K | 79.5K | 49.2K | 170K | 43.0K | 24.6K | 116K |
| Free Cash Flow | -681K | -1.56M | -2.60M | -3.77M | -2.65M | -4.07M | -4.93M | -6.05M | -5.00M | -10.5M | -6.49M |
| Ratios | |||||||||||
| ROE | -456.6% | -62.2% | -276.3% | -172.0% | -155.8% | -30.4% | -91.5% | -218.9% | -72.1% | -398.1% | -141.7% |
| ROA | -214.4% | -65.4% | -271.4% | -153.2% | -139.1% | -30.4% | -92.8% | -216.1% | -65.4% | -285.1% | -140.4% |
| Net Profit Margin | -2,983.4% | -2,937.3% | -1,523.0% | -1,841.5% | -1,023.0% | -557.2% | -2,846.3% | -2,946.4% | -1,248.2% | -1,686.0% | -25,180.9% |
| Debt to Equity | 0.17x | 0.01x | 0.00x | - | 0.06x | 0.01x | 0.01x | 0.05x | 0.02x | 0.04x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lexaria Bioscience Corp dividends
Lexaria Bioscience Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:15 on Aug 3, 2026.
Who owns Lexaria Bioscience Corp
- Insiders 3.21%
- Institutions 4.41%
- Public & others 92.38%
- Shares outstanding 2.11M
- Free float 1.61M
Top funds holding LEXX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Invenomic Institutional | 100.0K | 0.32% | -44.89% | Jul 2026 |
| Fidelity Extended Market Index | 8.65K | 0.41% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 2.13K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 1.74K | 0.08% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 680.00 | 0.03% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 591.00 | 0.03% | -0.17% | Aug 2026 |
Top institutions holding LEXX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Invenomic Capital Management, LP | 346K | 1.09% | -21.84% | Jun 2026 |
| Vanguard Capital Management, LLC | 298K | 0.94% | +34.25% | Jun 2026 |
| Geode Capital Management, LLC | 250K | 0.79% | -14.87% | Jun 2026 |
| Citadel Advisors Llc | 157K | 0.50% | +1,061.44% | Jun 2026 |
| The Toronto-Dominion Bank | 100K | 0.32% | -28.57% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 94.2K | 0.30% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 65.0K | 0.21% | +252.28% | Jun 2026 |
| UBS Group AG | 47.0K | 0.15% | -10.89% | Jun 2026 |
| Northern Trust Corp | 39.8K | 0.13% | +116.57% | Jun 2026 |
| State Street Corp | 39.3K | 0.12% | 0.00% | Jun 2026 |
| BlackRock Inc | 27.4K | 0.09% | 0.00% | Jun 2026 |
| StoneX Group Inc | 25.7K | 0.08% | 0.00% | Jun 2026 |
| Krilogy Advisors LLC | 24.2K | 0.08% | +22.90% | Jun 2026 |
| XTX Topco Ltd | 22.3K | 0.07% | -11.05% | Jun 2026 |
| Virtu Financial LLC | 18.9K | 0.06% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 15.3K | 0.05% | 0.00% | Jun 2026 |
| Vontobel Holding Ltd. | 15.2K | 0.05% | -33.96% | Jun 2026 |
| Bank of Montreal | 14.0K | 0.04% | 0.00% | Jun 2026 |
| BMO Capital Markets Corp. | 14.0K | 0.04% | 0.00% | Jun 2026 |
| Vanguard Global Advisers, LLC | 10.2K | 0.03% | 0.00% | Jun 2026 |
Lexaria Bioscience Corp company profile
- Company name
- Lexaria Bioscience Corp
- Ticker
- LEXX.US
- Exchange
- USA Stocks
- Listed since
- Oct 10, 2006
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- August
- Address
- 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7
- Phone
- 250 765 6424
- Website
- lexariabioscience.com
About Lexaria Bioscience Corp
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Lexaria Bioscience Corp management
6- Mr. Richard C. ChristopherCEO & Director · born 1970
- Mr. John M. Docherty M.Sc.Chairman of the Scientific Advisory Board, Chief Scientific Officer, President & Director · born 1969
- Mr. Michael Shankman CPAChief Financial Officer · born 1961
- Ms. Kristin HamiltonDirector of Operations
- Ms. Vanessa CarleHead of Legal
- Dr. C. Michael Gibson M.D., M.S.Chief Medical Advisor & Member of Scientific Advisory Board